STOCKHEAD ARTICLE
Exopharm will conduct a research collaboration with Japan’s Showa Denko Materials as its LEAP technology shows promise at reducing a major obstacle in the advancement of exosomes as a new form of regenerative medicine for diseases such as cancer.
Melbourne Biotech company Exopharm (ASX:EX1) has announced it will undertake a research collaboration with Japan’s Showa Denko Materials Co (SDMC), a world leading international chemicals manufacturing group.
Under the feasibility study agreement SDMC will evaluate Exopharm’s LEAP – Ligand-based Exosome Affinity Purification – technology platform within its Yokohama regenerative medicine business unit.
“Showa Denko is an established international supplier of drug and other chemical substances and if the feasibility study is successful, exosomes purified using LEAP could be yet another valuable product in their portfolio,” Exopharm chief commercial officer Dr Chris Baldwin said.